Clinuvel Pharmaceuticals マネジメント
マネジメント 基準チェック /24
Clinuvel Pharmaceuticalsの CEO はPhilippe Wolgenで、 Nov2005年に任命され、 の在任期間は 19.08年です。 の年間総報酬はA$ 3.74Mで、 47.2%給与と52.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の6.86%を直接所有しており、その価値はA$ 44.66M 。経営陣と取締役会の平均在任期間はそれぞれ0.9年と5年です。
主要情報
Philippe Wolgen
最高経営責任者
AU$3.7m
報酬総額
| CEO給与比率 | 47.2% |
| CEO在任期間 | 19yrs |
| CEOの所有権 | 6.9% |
| 経営陣の平均在職期間 | less than a year |
| 取締役会の平均在任期間 | 5yrs |
経営陣の近況
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | AU$4m | AU$2m | AU$36m |
| Mar 31 2024 | n/a | n/a | AU$33m |
| Dec 31 2023 | n/a | n/a | AU$30m |
| Sep 30 2023 | n/a | n/a | AU$30m |
| Jun 30 2023 | AU$6m | AU$2m | AU$31m |
| Mar 31 2023 | n/a | n/a | AU$29m |
| Dec 31 2022 | n/a | n/a | AU$26m |
| Sep 30 2022 | n/a | n/a | AU$24m |
| Jun 30 2022 | AU$7m | AU$1m | AU$21m |
| Mar 31 2022 | n/a | n/a | AU$22m |
| Dec 31 2021 | n/a | n/a | AU$24m |
| Sep 30 2021 | n/a | n/a | AU$24m |
| Jun 30 2021 | AU$5m | AU$2m | AU$25m |
| Mar 31 2021 | n/a | n/a | AU$23m |
| Dec 31 2020 | n/a | n/a | AU$21m |
| Sep 30 2020 | n/a | n/a | AU$18m |
| Jun 30 2020 | AU$3m | AU$2m | AU$15m |
| Mar 31 2020 | n/a | n/a | AU$15m |
| Dec 31 2019 | n/a | n/a | AU$15m |
| Sep 30 2019 | n/a | n/a | AU$16m |
| Jun 30 2019 | AU$1m | AU$894k | AU$18m |
| Mar 31 2019 | n/a | n/a | AU$17m |
| Dec 31 2018 | n/a | n/a | AU$16m |
| Sep 30 2018 | n/a | n/a | AU$15m |
| Jun 30 2018 | AU$2m | AU$818k | AU$13m |
報酬と市場: Philippeの 総報酬 ($USD 2.43M ) は、 Australian市場 ($USD 927.25K ) の同規模の企業の平均を上回っています。
報酬と収益: Philippeの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Philippe Wolgen (61 yo)
19yrs
在職期間
AU$3,742,412
報酬
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, MD & Director | 19yrs | AU$3.74m | 6.86% A$ 44.7m | |
| Chief Scientific Officer | 12.2yrs | AU$782.61k | 0.38% A$ 2.5m | |
| Chief Financial Officer | less than a year | データなし | データなし | |
| Chief Operations Officer | no data | データなし | データなし | |
| Head of Australian Operations & Investor Relations | no data | データなし | データなし | |
| Senior Vice President of Regulatory Affairs | less than a year | データなし | データなし | |
| Head of Quality Assurance & Drug Safety | less than a year | データなし | データなし | |
| Company Secretary | less than a year | データなし | データなし |
0.9yrs
平均在職期間
経験豊富な経営陣: CUVの経営陣は 経験豊富 とはみなされません ( 0.9年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, MD & Director | 19.1yrs | AU$3.74m | 6.86% A$ 44.7m | |
| Non-Executive Director | less than a year | データなし | データなし | |
| Non-Executive Director | less than a year | データなし | データなし | |
| Non-Executive Director | 5.2yrs | AU$80.00k | 0.00084% A$ 5.5k | |
| Non-Executive Chairman | 5yrs | AU$91.67k | 0.0063% A$ 41.0k | |
| Non-Executive Director | 6.8yrs | AU$75.00k | 0.028% A$ 180.4k | |
| Non-Executive Director | less than a year | データなし | データなし |
5.0yrs
平均在職期間
経験豊富なボード: CUVの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。